You are here

  • Home
  • Archive
  • Volume 78, Issue 5
  • Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Article metrics

Article menu
Download PDFPDF
Systemic lupus erythematosus
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

 

Online download statistics by month:

Online download statistics by month: January 2019 to September 2024

AbstractFullPdf
Jan 201910466446
Feb 2019177511275
Mar 201911574130
Apr 2019103512592
May 20194189664
Jun 20193514332
Jul 20192345338
Aug 20191523017
Sep 2019942519
Oct 20191271922
Nov 20191292721
Dec 20191662020
Jan 20201233322
Feb 20201971713
Mar 2020821514
Apr 2020731411
May 20202252819
Jun 20201891210
Jul 202013397
Aug 20207135
Sep 20201321611
Oct 20201041511
Nov 2020109129
Dec 2020132168
Jan 20211481819
Feb 2021711617
Mar 2021971512
Apr 2021991312
May 20211102525
Jun 2021261712
Jul 202122147
Aug 2021281617
Sep 2021251711
Oct 20211193417
Nov 20211962715
Dec 20212792413
Jan 2022109104
Feb 20221702517
Mar 20221433327
Apr 2022132126
May 20223042019
Jun 20221782123
Jul 20221622313
Aug 20222232714
Sep 20222483719
Oct 20222953629
Nov 2022197219
Dec 2022167206
Jan 20232823416
Feb 20232764016
Mar 20232021511
Apr 20231992921
May 20232263618
Jun 20233363025
Jul 20231441717
Aug 20233733633
Sep 20233281917
Oct 20232882915
Nov 20236213114
Dec 2023345336
Jan 2024227193
Feb 20242402314
Mar 20241362013
Apr 20241822814
May 20241872013
Jun 20241391910
Jul 20242442515
Aug 20241721611
Sep 20242473522
Total1719619201303